Scarica l'app Stockscreener
9.58
0.62%
-0.06
Dopo l'orario di chiusura:
9.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$9.64
Aprire:
$9.62
Volume 24 ore:
1.70M
Relative Volume:
0.74
Capitalizzazione di mercato:
$2.86B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-28.18
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-0.31%
1M Prestazione:
+1.70%
6M Prestazione:
-7.08%
1 anno Prestazione:
-22.93%
Intervallo 1D:
$9.555
$9.73
Intervallo di 1 settimana:
$9.465
$9.83
Portata 52W:
$8.785
$14.03
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.58 | 2.86B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics (NASDAQ:FOLD) shareholders have endured a 26% loss from investing in the stock a year ago - Simply Wall St
13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inspire Investing LLC - MarketBeat
Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN
Leerink Partnrs Issues Optimistic Estimate for FOLD Earnings - MarketBeat
Research Analysts Set Expectations for FOLD Q2 Earnings - MarketBeat
Assenagon Asset Management S.A. Has $4.49 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential - Yahoo Finance
Jefferies Initiates Coverage of Amicus Therapeutics (FOLD) with Buy Recommendation - MSN
Cantor Fitzgerald Reaffirms Overweight Rating for Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat
Enzyme Replacement Therapy Market Deep Research Report with - openPR
When (FOLD) Moves Investors should Listen - Stock Traders Daily
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Price Target at $16.88 - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook - MSN
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpStill a Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Earns Hold Rating from Needham & Company LLC - MarketBeat
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts - Benzinga
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week - Yahoo Finance
Fabry Disease Treatment Market Top Companies StudySanofi SA, - openPR
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewswire
Amicus Therapeutics Reports Stellar 32% Revenue Growth to $528.5M, Eyes $1B Sales Target - StockTitan
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Amicus Therapeutics stock hits 52-week low at $9.01 By Investing.com - Investing.com Canada
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year LowShould You Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at $9.01 - Investing.com
Principal Financial Group Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Principal Financial Group Inc. - MarketBeat
How the (FOLD) price action is used to our Advantage - Stock Traders Daily
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Amicus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
JPMorgan Chase & Co. Sells 1,984,751 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Trimmed by JPMorgan Chase & Co. - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Short Interest Update - MarketBeat
Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues - Simply Wall St
Amicus Therapeutics: Cheap Heading Into 2025 (NASDAQ:FOLD) - Seeking Alpha
Stifel Financial Corp Sells 21,615 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Geode Capital Management LLC Acquires 80,926 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):